Mglu2 / 3 antagonists for the treatment of intellectual disabilities

MA39901AUndetermined Publication Date: 2017-03-01F HOFFMANN LA ROCHE & CO AG +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MA39901
Authority / Receiving Office: MA · MA
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2014-04-23
Filing Date: 2015-04-20
Publication Date: 2017-03-01

Application Information

Patent Timeline

23 Apr 2014

Priority

20 Apr 2015

Application

MA39901

01 Mar 2017

Publication

MA39901A

IPC: A61K31/444; A61K31/519; A61P25/28

CPC: C07D213/34; C07D487/04; A61K31/444; A61K31/519; A61P25/00; A61P25/28; A61P43/00

Inventors: BALLARD Theresa M.; GATTI MCARTHUR Silvia

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mglu2 / 3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.

Need to check novelty before this filing date? Find Prior Art